A Community-transmitted Case of Severe Acute Respiratory Distress Syndrome (SARS) Due to SARS-CoV-2 in the United States
- PMID: 32227197
- PMCID: PMC7197621
- DOI: 10.1093/cid/ciaa347
A Community-transmitted Case of Severe Acute Respiratory Distress Syndrome (SARS) Due to SARS-CoV-2 in the United States
Abstract
This is the first known community transmission case of the novel coronavirus disease (COVID-19) in the United States, with significant public health implications. Diagnosis of COVID-19 is currently confirmed with PCR based testing of appropriate respiratory samples. Given the absence of travel or known exposure history, this patient did not meet the criteria for testing according to CDC guidelines at the time of her presentation. Since this case, any patient with severe disease (eg, ARDS or pneumonia) requiring hospitalization without an explanatory diagnosis can be tested even if no clear source of exposure is identified. While influencing national health policies for revising screening criteria, this case also highlighted significant knowledge gaps in diagnosis and treatment and a desperate need for early, widespread, fast and cheap testing for COVID-19.
Keywords: COVID-19; SARS-CoV-2; community transmission; index case; novel coronavirus.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Similar articles
-
Clinical course and serial chest ultra-low-dose CT findings in a patient with COVID-19 treated with remdesivir.Minerva Med. 2021 Aug;112(4):516-518. doi: 10.23736/S0026-4806.20.06644-6. Minerva Med. 2021. PMID: 34269015 No abstract available.
-
Severe Covid-19.N Engl J Med. 2020 Dec 17;383(25):2451-2460. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15. N Engl J Med. 2020. PMID: 32412710 Review. No abstract available.
-
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.Pain Physician. 2020 Mar;23(2):E71-E83. Pain Physician. 2020. PMID: 32214286
-
Severe COVID-19 Infections-Knowledge Gained and Remaining Questions.JAMA Intern Med. 2021 Jan 1;181(1):9-11. doi: 10.1001/jamainternmed.2020.6047. JAMA Intern Med. 2021. PMID: 32945833 No abstract available.
-
Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.Biopreserv Biobank. 2020 Dec;18(6):492-502. doi: 10.1089/bio.2020.0066. Epub 2020 Jul 23. Biopreserv Biobank. 2020. PMID: 32726140 Review.
Cited by
-
Study on the clinical characteristics, treatment, and outcome influencing factors of severe pneumonia complicated with ARDS.Medicine (Baltimore). 2024 Nov 8;103(45):e40316. doi: 10.1097/MD.0000000000040316. Medicine (Baltimore). 2024. PMID: 39533637 Free PMC article.
-
In silico evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment.World J Biol Chem. 2023 Jul 27;14(4):72-83. doi: 10.4331/wjbc.v14.i4.72. World J Biol Chem. 2023. PMID: 37547340 Free PMC article.
-
Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials.Front Pharmacol. 2022 Sep 8;13:971890. doi: 10.3389/fphar.2022.971890. eCollection 2022. Front Pharmacol. 2022. PMID: 36160434 Free PMC article. Review.
-
Construct validation of the COVID-19 Cavalier Scale: Analysis of indirect effects with optimism on likelihood to travel.Transp Res Interdiscip Perspect. 2022 Mar;13:100538. doi: 10.1016/j.trip.2022.100538. Epub 2022 Jan 7. Transp Res Interdiscip Perspect. 2022. PMID: 35018341 Free PMC article.
-
Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians.J Pharm Technol. 2021 Feb;37(1):62-74. doi: 10.1177/8755122520967634. Epub 2020 Oct 30. J Pharm Technol. 2021. PMID: 34752546 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous

